NanOlogy LLC’s Purcision™ Intratumoral Cancer Technology Gains Spotlight with CEO David J. Arthur Interview

NanOlogy, LLC CEO David J. Arthur discussed the company’s PURCISION™ technology in an interview with CEOCFO Magazine, explaining how the platform creates large surface area microparticles of pure cancer drugs optimized for direct intratumoral delivery to improve solid tumor treatment while minimizing systemic toxicity. He highlighted the feasibility of the technology across multiple small molecule drugs and its potential to enhance tumor response and support immune priming without increased toxicity, positioning NanOlogy’s approach as a promising advancement in oncology.